> Detailanzeige

Lainka, Elke; Baehr, Melanie; Raszka, Bernadette; Haas, Johannes-Peter; Hügle, Boris; Fischer, Nadine; Foell, Dirk; Hinze, Claas; Weissbarth-Riedel, Elisabeth; Kallinich, Tilmann; Horneff, Gerd; Windschall, Daniel; Lilienthal, Eggert; Niehues, Tim; Neudorf, Ulrich; Berendes, Rainer; Küster, Rolf-Michael; Oommen, Prasad Thomas; Rietschel, Christoph; Lutz, Thomas; Weller-Heinemann, Frank; Tenbrock, Klaus; Heubner, Georg Leonhard; Klotsche, Jens;

Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis – data from the German AID-registry
  • Beteiligte: Lainka, Elke; Baehr, Melanie; Raszka, Bernadette; Haas, Johannes-Peter; Hügle, Boris; Fischer, Nadine; Foell, Dirk; Hinze, Claas; Weissbarth-Riedel, Elisabeth; Kallinich, Tilmann; Horneff, Gerd; Windschall, Daniel; Lilienthal, Eggert; Niehues, Tim; Neudorf, Ulrich; Berendes, Rainer; Küster, Rolf-Michael; Oommen, Prasad Thomas; Rietschel, Christoph; Lutz, Thomas; Weller-Heinemann, Frank; Tenbrock, Klaus; Heubner, Georg Leonhard; Klotsche, Jens;
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: Pediatric Rheumatology
  • Sprache: Englisch
  • DOI: 10.1186/s12969-021-00510-8
  • ISSN: 1546-0096
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a complex disease with dysregulation of the innate immune system driven by cytokines. A major role is ascribed to interleukin-1β (IL-1β), supporting the autoinflammatory character of the disease and offering an effective blocking mechanism for treatment. Here we present clinical practice data from the German AID-registry for patients treated with IL-1 inhibition (IL-1i).</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>In 2009 a clinical and research consortium (AID-Net) was established, including an online AID-registry. Patients with documented sJIA diagnosis were identified. Data for this retrospective IL-1i study were recorded by 17 centers. Response to treatment was evaluated according to Wallace criteria and additionally by an own classifying clinical response system.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In 6 years, 202 patients with confirmed sJIA were recorded in the AID-registry. Out of these, 111 children received therapy with Anakinra (ANA) (<jats:italic>n</jats:italic> = 84, 39 f) and/or Canakinumab (CANA) (<jats:italic>n</jats:italic> = 27, 15 f) at a median age of 8.7 y (range 0.6–19.1). During the first 12 months 75/111 (ANA 55, CANA 20) patients were evaluated according to Wallace criteria (achievement of inactive disease 28/55 and 17/20, remission over 6 months under medication 13/55 and 7/20 cases). Over the whole period of time, clinical response was preserved in the majority of patients (ANA 54/80, CANA 20/27). Arthritis mostly persisted in polyarticular (PA) courses. During treatment with IL-1i concomitant medication could be tapered in about 15%. IL-1i was discontinued in 59/111 patients. 45 (15) adverse events (AE)s in ANA (CANA) treated patients (19.7 (26.6) AE/100 ANA (CANA) exposure years, 95%CI: 14.4–26.4 (14.9–43.9)) were reported.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In a large cohort of sJIA patients from Germany, we can confirm an overall favorable clinical response to both available IL-1 blocking agents. IL-1i was well tolerated with acceptable safety and effectiveness in a real-life clinical setting.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang